"first line treatment" trang 2 - tải miễn phí từ tailieuXANH
Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status

Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status
9    43    1
Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment
8    83    0
Báo cáo toán học:

Báo cáo toán học: "MAINTENANCE HORMONAL TREATMENT IMPROVES PROGRESSION FREE SURVIVAL AFTER A FIRST LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST CANCER"
6    59    0
Báo cáo khoa học:

Báo cáo khoa học: "Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis"
7    37    0
báo cáo khoa học:

báo cáo khoa học: "First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib"
10    52    0
báo cáo hóa học:

báo cáo hóa học:" High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia"
10    44    0
báo cáo hóa học:

báo cáo hóa học:" High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo"
6    33    0
Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- and second-line antiretroviral therapy: A study protocol for a prospective observational study in the centre region of Cameroon (EDCTP READY-study)

Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- and second-line antiretroviral therapy: A study protocol for a prospective observational study in the centre region of Cameroon (EDCTP READY-study)
11    79    0
Magnitude and causes of first-line antiretroviral therapy regimen changes among HIV patients in Ethiopia: A systematic review and meta-analysis

Magnitude and causes of first-line antiretroviral therapy regimen changes among HIV patients in Ethiopia: A systematic review and meta-analysis
15    45    0
Patterns of regional lymph node failure of locally advanced hypopharyngeal squamous cell carcinoma after first-line treatment with surgery and/or intensitymodulated radiotherapy

Patterns of regional lymph node failure of locally advanced hypopharyngeal squamous cell carcinoma after first-line treatment with surgery and/or intensitymodulated radiotherapy
11    52    0
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: Results from a prospective observational study (CAPRO)

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: Results from a prospective observational study (CAPRO)
10    69    0
CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer

CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer
8    58    0
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologicallyselected advanced colorectal cancer patients: The CIFRA study protocol

Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologicallyselected advanced colorectal cancer patients: The CIFRA study protocol
9    47    0
Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: A lesion-based and patient-based analysis

Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: A lesion-based and patient-based analysis
10    53    0
Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/ recurrent gastric cancer previously untreated with chemotherapy

Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/ recurrent gastric cancer previously untreated with chemotherapy
7    77    0
The PANDA study: A randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

The PANDA study: A randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
11    63    0
Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia

Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia
6    57    0
Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
10    80    0
Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: Results from the randomized phase III SELECT BC trial

Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: Results from the randomized phase III SELECT BC trial
10    72    0
Study protocol for an open-label, singlearm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma

Study protocol for an open-label, singlearm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
8    103    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.